Can Pfizer’s pipeline offset looming patent cliffs despite a stronger 2025 forecast?

Pfizer Inc. (NYSE: PFE), the American multinational pharmaceutical and biotechnology corporation, posted second-quarter 2025 results that surpassed market expectations and raised its full-year profit guidance. The stronger earnings outlook and a disciplined cost-saving program have reassured investors in the short term. However, looming patent expirations on blockbuster therapies such as Eliquis, Ibrance, and Xtandi present a significant long-term challenge. Against this backdrop, the critical question for the pharmaceutical giant is whether its oncology and rare disease pipeline can generate sufficient growth to offset these looming losses.

The broader pharmaceutical industry is bracing for what is being described as the most significant patent cliff in decades, with an estimated USD 180 billion in annual revenue at risk between 2027 and 2028. Pfizer’s trajectory offers a case study in how large-cap pharma companies are balancing near-term financial discipline with the long-term imperative of innovation.

What are the key patent expirations threatening Pfizer’s long-term revenue stability?

Pfizer faces some of the industry’s most impactful patent expirations within the next three to five years. The blood thinner Eliquis, co-marketed with Bristol Myers Squibb, is projected to lose exclusivity by 2026. With annual sales exceeding USD 10 billion, the erosion of Eliquis revenue could leave a substantial gap in Pfizer’s earnings base. Meanwhile, the oncology therapy Ibrance, a leading treatment for breast cancer, will lose exclusivity in major markets around 2027. Prostate cancer treatment Xtandi is also approaching its own patent cliff, compounding the revenue risks facing Pfizer.

In addition, other important products such as Prevnar and Xeljanz face growing competition, particularly from biosimilars and alternative vaccines. Collectively, analysts estimate Pfizer could see USD 17–18 billion in annualized revenue decline tied to these expirations. For context, that figure represents more than one-quarter of the company’s current annual revenue guidance of USD 61–64 billion for 2025.

How is Pfizer using its oncology and rare disease pipeline to mitigate revenue losses?

To counteract these challenges, Pfizer has aggressively expanded its pipeline, particularly in oncology and biologics. The acquisition of Seagen in 2023 significantly bolstered Pfizer’s presence in antibody-drug conjugates (ADCs), a high-growth therapeutic area with potential to reshape cancer treatment. Seagen added a portfolio of 12 ADC candidates in various stages of development, providing Pfizer with multiple shots on goal as it seeks to build new blockbusters.

Pfizer’s management has emphasized that biologics will account for roughly 65 percent of the company’s revenue by 2030, compared to less than 30 percent a decade ago. Late-stage oncology trials are viewed as crucial catalysts, with particular focus on therapies targeting breast, lung, and hematologic cancers. Beyond oncology, Pfizer is investing in rare diseases, where therapies can command premium pricing and longer exclusivity periods due to smaller patient populations.

The company is also advancing vaccines, including next-generation formulations for respiratory syncytial virus (RSV) and pneumococcal disease, which are expected to provide incremental but steady revenue streams.

How do Pfizer’s peers Merck, Bristol Myers Squibb, and AstraZeneca compare in managing their patent cliffs?

Pfizer is not alone in facing substantial revenue losses from expiring patents. Merck & Co. is preparing for the loss of exclusivity on Keytruda, its USD 30 billion-per-year immuno-oncology therapy. To delay the impact, Merck has introduced a subcutaneous formulation of Keytruda, which may extend its market share and partially shield against biosimilar erosion post-2028.

Bristol Myers Squibb is also heavily exposed, with Revlimid already facing generic erosion and Eliquis approaching its own expiration. The American pharma major has sought to diversify through pipeline deals, including a USD 11 billion agreement with BioNTech to co-develop bispecific cancer therapies.

AstraZeneca, meanwhile, has laid out an ambitious target to nearly double its revenue to USD 80 billion by 2030. Its strategy hinges on a robust oncology portfolio, rare disease expansion through its Alexion acquisition, and aggressive investment in cardiometabolic therapies. AstraZeneca’s proactive pipeline positioning is seen by institutional investors as a template for how to navigate looming cliffs while maintaining growth.

What broader industry trends are shaping pharma strategies as patent cliffs approach?

Across the sector, the sheer scale of the patent cliff has triggered a wave of acquisitions, licensing deals, and portfolio restructuring. Industry analysts estimate that between 2027 and 2028, USD 180 billion in annual revenue will lose exclusivity protections, exposing drugmakers to generic and biosimilar competition. The focus has shifted from defending individual blockbuster drugs to building diversified portfolios across biologics, advanced therapies, and niche markets.

For many companies, biologics and complex therapies such as ADCs, cell therapies, and gene therapies are the preferred strategy because these products are harder to replicate, offering extended protection against biosimilars. At the same time, payers and regulators are applying increasing pressure to reduce costs, meaning that pricing power will be tested even in high-value categories.

How do institutional investors view Pfizer’s updated earnings forecast in light of its long-term risks?

Pfizer’s decision to raise its 2025 adjusted EPS guidance to USD 2.90–3.10, up from a prior range of USD 2.80–3.00, reflects confidence in its near-term execution. The reaffirmed revenue guidance of USD 61–64 billion underscores management’s belief that operational discipline and ongoing cost savings will stabilize performance. Investors welcomed the Q2 beat, which saw EPS of USD 0.78 against expectations of USD 0.58, but institutional sentiment remains cautious.

The consensus among analysts is that Pfizer’s current valuation, with shares trading near USD 24–25, reflects skepticism about its ability to sustain growth beyond the next two to three years. While the cost-saving program targeting USD 7.2–7.7 billion by 2027 provides earnings visibility, the long-term outlook hinges on the success of late-stage pipeline assets. Institutional investors have described their stance as “cautiously constructive”—encouraged by cost discipline, but unwilling to price in sustained growth until clinical trial results provide more clarity.

What factors will determine whether Pfizer can successfully navigate the patent cliff era?

Ultimately, Pfizer’s ability to offset looming patent expirations will depend on a combination of pipeline success, disciplined execution, and external factors such as drug pricing regulation.

The key determinants of Pfizer’s ability to navigate the patent cliff era will be its execution across multiple fronts. Oncology trial outcomes are expected to play a decisive role, with success in late-stage antibody-drug conjugate programs from the Seagen portfolio potentially delivering multi-billion-dollar revenue opportunities. Rare disease expansion will also matter, as premium therapies in highly specialized indications can provide durable growth, though they will come from smaller patient populations. The regulatory environment will be another influential factor, since ongoing U.S. drug pricing reforms and shifting global reimbursement policies will directly impact the profitability of both established and pipeline products. Finally, cost discipline remains critical, with the full realization of the USD 7.7 billion savings target by 2027 positioned to preserve earnings stability as top-line pressures from patent expirations intensify.

If Pfizer can deliver a steady cadence of approvals while maintaining operational discipline, it may yet emerge from the patent cliff era with renewed momentum. Failure to do so, however, could see the company’s revenue base erode at a faster pace than peers with deeper or more diversified pipelines.

Is Pfizer positioned strongly enough to sustain long-term growth?

Pfizer’s second-quarter 2025 results and raised guidance provided a short-term boost in confidence, but the company’s long-term trajectory remains tied to the success of its oncology and rare disease pipeline. Patent expirations for Eliquis, Ibrance, and Xtandi are unavoidable, and their combined impact represents one of the largest single-company revenue risks in the industry.

Compared with peers such as Merck, Bristol Myers Squibb, and AstraZeneca, Pfizer’s strategy is credible but not yet fully proven. Its acquisitions, pipeline investments, and cost-saving programs demonstrate a proactive response, but investors and analysts agree that execution in the next two to three years will determine whether Pfizer emerges from the patent cliff era as a revitalized growth story or as a cautionary tale of over-reliance on legacy blockbusters.